Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
90 hedge funds and large institutions have $523M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2017 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 31 increasing their positions, 14 reducing their positions, and 14 closing their positions.
386% more call options, than puts
Call options by funds: $4.24M | Put options by funds: $872K
121% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 14
107% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 14
20% more funds holding
Funds holding: 75 → 90 (+15)
11% less capital invested
Capital invested by funds: $585M → $523M (-$62.6M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$20.2M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$13.8M |
| 3 |
JP Morgan Chase
New York
|
+$12.1M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$8.78M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YU
Yale University
New Haven,
Connecticut
|
-$9.35M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.45M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$3.6M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$2.79M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$2.08M |
BHVN Hedge Fund Activity: Q4 2017 in Review
90 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q4 2017, worth a combined $523M — down 11% from $585M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new BHVN positions and 14 closed out — a net gain of 15 holders — while 31 added to existing stakes and 14 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $20.2M. The largest seller was Yale University, exiting entirely with an estimated $9.35M sold.
- 90 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q4 2017, up from 75 in Q3 2017.
- Funds reported $523M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q4 2017, down 11% quarter-over-quarter.
- 29 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q4 2017 and 14 closed out, a net change of +15 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q4 2017 was AllianceBernstein, an estimated $20.2M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q4 2017 was Yale University, an estimated $9.35M sold.
Based on aggregated 13F filings for Q4 2017.